Edition:
United Kingdom

Lipocine Inc (LPCN.OQ)

LPCN.OQ on NASDAQ Stock Exchange Capital Market

1.18USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$1.18
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
62,607
52-wk High
$5.32
52-wk Low
$1.16

Chart for

About

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product... (more)

Overall

Beta: 1.04
Market Cap(Mil.): $81.66
Shares Outstanding(Mil.): 20.67
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Lipocine Announces Settlement Of Securities Class Action Lawsuit

* LIPOCINE ANNOUNCES SETTLEMENT OF SECURITIES CLASS ACTION LAWSUIT

16 Feb 2018

BRIEF-Lipocine Announces $10 Mln Loan And Security Agreement With Silicon Valley Bank

* LIPOCINE ANNOUNCES $10 MILLION LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK Source text for Eikon: Further company coverage:

08 Feb 2018

BRIEF-Lipocine Says FDA's BRUDAC Voted 6 In Favor & 13 Against Benefit/Risk Profile Of Tlando

* LIPOCINE - FDA'S BRUDAC VOTED 6 IN FAVOR & 13 AGAINST BENEFIT/RISK PROFILE OF CO'S ORAL TESTOSTERONE PRODUCT CANDIDATE FOR TRT IN ADULT MALES, TLANDO

10 Jan 2018

BRIEF-Lipocine Says On Jan 5, Co, Unit, Silicon Valley Bank Entered Into Loan, Security Agreement

* LIPOCINE INC SAYS ON JAN 5, CO, UNIT, SILICON VALLEY BANK ("SVB") ENTERED INTO A LOAN AND SECURITY AGREEMENT -SEC FILING

09 Jan 2018

BRIEF-Lipocine says ‍FDA assigned a new prescription drug user fee act goal date of May 8, 2018 for Tlando​

* U.S. FDA extends review for Tlando™; advisory committee meeting date of January 10, 2018 remains unchanged

17 Nov 2017

BRIEF-Lipocine Inc Q3 loss per share $0.22

* Lipocine announces financial and operational results for the third quarter and nine months ended September 30, 2017

08 Nov 2017

BRIEF-Lipocine says FDA has scheduled bone, reproductive and urologic drugs advisory committee meeting on January 10, 2018

* Lipocine -‍ announced FDA has scheduled bone, reproductive and urologic drugs advisory committee meeting on January 10, 2018 to discuss NDA for Tlando​

18 Oct 2017

BRIEF-Lipocine Inc files for mixed shelf of up to $150 million

* Lipocine Inc files for mixed shelf of up to $150 million - SEC filing‍​ Source text for Eikon: (http://bit.ly/2zlVhiU) Further company coverage:

13 Oct 2017

BRIEF-Lipocine - ‍PTAB of USPTO issued a motions decision in interference case between Clarus Therapeutics and Lipocine Inc​

* Lipocine - ‍ PTAB of USPTO issued a motions decision based on each party's motions in interference case between Clarus Therapeutics and Lipocine Inc​

21 Sep 2017

BRIEF-Lipocine announces FDA Advisory Committee meeting for TLANDO

* Lipocine Inc - advisory committee meeting date has not been finalized but will occur prior to PDUFA goal date of February 8, 2018 Source text for Eikon: Further company coverage:

20 Sep 2017

Earnings vs. Estimates